Adverum Biotechnologies Inc logo

ADVM

Adverum Biotechnologies Inc

$1.36

Earnings Summary

Revenue
$0Mn
Net Profits
$-37.91Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Adverum Biotechnologies Inc’s revenue fell -100% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Adverum Biotechnologies Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Adverum Biotechnologies Inc’s net profit fell -33.31% since last year same period to $-37.91Mn in the Q1 2022. On a quarterly growth basis, Adverum Biotechnologies Inc has generated -10.17% fall in its net profits since last 3-months.

Net Profit Margins:

Adverum Biotechnologies Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Adverum Biotechnologies Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Adverum Biotechnologies Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.34
EPS Estimate Current Year
-0.34

Highlights

EPS Estimate Current Quarter:

Adverum Biotechnologies Inc’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a -9.68% fall from last quarter’s estimates.

EPS Estimate Current Year:

Adverum Biotechnologies Inc’s earning per share (EPS) estimates for the current year stand at -0.34.

Key Ratios

Key ratios of the Adverum Biotechnologies Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.38
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.5
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Adverum Biotechnologies Inc’s earning per share (EPS) fell -31.03% since last year same period to -0.38 in the Q1 2022. This indicates that the Adverum Biotechnologies Inc has generated -31.03% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adverum Biotechnologies Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adverum Biotechnologies Inc’s return on equity (ROE) stands at -0.5.

Dividend Per Share (DPS):

Adverum Biotechnologies Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.31
-0.38
-22.58%

Company Information

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

Organisation
Adverum Biotechnologies Inc
Headquarters
Redwood City, California, US
Employees
167
Industry
Health Technology
CEO
Leone Patterson